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Acute myeloid leukaemia (AML) is an aggressive haematologic dis‐
order and despite advances in diagnosis and treatment, AML‐related 
mortality remains high. Acute myeloid leukaemia is characterized by 
accumulation of undifferentiated cells in the bone marrow and blood. 
Aberrant control of cell growth and metabolism in haematopoietic 
precursors appear as underlying mechanisms of leukaemogenesis. 
Unraveling the molecular mechanisms that control proliferation 
in myeloid cells is crucial for the development of new therapeutic 
approaches. In this sense, long non‐coding RNAs (lncRNAs) have 
emerged as major players in disease pathogenesis.1,2
Lymphoid enhancer‐binding factor 1 (LEF1) Antisense RNA 1, 
LEF1 antisense RNA 1 (LEF1‐AS1), is a highly conserved transcript 
and several lines of evidence suggest an important role of this ln‐
cRNA in the haematopoietic system.3‐5 However, this is the first 
study, to our knowledge, to characterize the role of LEF1‐AS1 in my‐
eloid cells.
A recent study identified an unprocessed non‐coding transcript 
in the locus and demonstrated that this transcript regulates LEF1 
coding expression in pancreatic and colorectal carcinoma cell lines.6 
The function of LEF1‐AS1 in these cell lines was dependent on the 
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Abstract
LEF1 antisense RNA 1 (LEF1‐AS1) is an antisense long non‐coding RNA encoded in 
the lymphoid enhancer‐binding factor 1 (LEF1) locus. LEF1‐AS1 is a conserved tran‐
script dysregulated in hematopoiesis. This study aimed to functionally characterize 
the role of this transcript in myeloid malignancy and explore a possible regulatory 
effect of LEF1‐AS1 upon LEF1. We show that LEF1‐AS1 is highly expressed in normal 
hematopoietic stem cells but barely detectable in myeloid malignant cell lines. 
Additionally, bone marrow cells from myelodysplastic syndrome (n=12) and acute 
myeloid malignancy patients (n=28) expressed significantly reduced levels of LEF1‐
AS1 compared to healthy controls (n=15). Artificial LEF1‐AS1 over‐expression inhib‐
ited proliferation in HL60 and led to an upregulation of tumor suppressors p21 and 
p27,	 and	 reduced	 ERK1/2	 activation.	 Unexpectedly,	 no	 underlying	modulation	 of	
LEF1 was detected. Ectopic expression of LEF1‐AS1 also inhibited proliferation in 
HELA, a cell line lacking endogenous expression of LEF1, supporting a LEF1‐inde‐
pendent mechanism. Additionally, transient over‐expression of LEF1‐AS1 in AML pa‐
tient cells also led to reduced proliferation and colony formation capacity. We used a 
mass spectrometry‐based proteomics approach. Proteomic quantification identified 
the modulation of an important metabolic regulator, Fumarase, and concomitant ac‐
cumulation of the metabolite fumarate.
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unspliced transcript and ultimately on the regulation of LEF1.6 Based 
on this evidence and as LEF1 coding gene has an established role 
in myeloid malignancy,7,8 we suspected a cis‐regulatory mechanism 
between the antisense non‐coding transcript and LEF1 in the hae‐
matopoietic system. To investigate the role of LEF1‐AS1 in the reg‐
ulation of LEF1 and myeloid malignancy pathogenesis, we used a 
stable transfection approach to overexpress the transcript in myeloid 
cell	line	HL60.	Stably	transfected	cells	were	obtained	by	DMRIE(1,2-
dimyristyloxypropyl‐3‐dimethyl‐hydroxy ethyl ammonium bromide) 
-C-mediated	transfection	using	pcDNA	vector	containing	full	length	
LEF1-AS1	or	empty	pcDNA	vector,	 and	3	weeks	of	geneticin	 selec‐
tion. This method was adapted from Grinstein et al9 and details are 
presented in Supplementary information. Unexpectedly, we could 
not detect any significant alteration of LEF1 expression after over‐
expression	of	LEF1-AS1	(Figure	1A).	Despite	the	lack	of	effect	upon	
LEF1, we observed that LEF1‐AS1 overexpression led to inhibition of 
proliferation as shown by two different proliferation‐specific assays. 
Carboxyfluorescein succinimidyl ester (CFSE) labelling was used to 
trace cell divisions in HL60 stably transfected cells. Flow cytometry 
analysis showed that cells overexpressing LEF1‐AS1 underwent less 
cell divisions (Figure 1C; Supplementary). Additionally, flow cytometry 
measurement	of	Ki67	staining	(proliferation	marker)	was	also	was	sig‐
nificantly	reduced	in	LEF1-AS1-HL60	synchronized	cells	(Figure	1D).
In line with this reduction in proliferation, an increased expres‐
sion	of	tumour	suppressors	CDKN1A	(p21)	and	CDKN1B	(p27)	was	
detected in the mRNA and protein levels (Figure 1B; Supplementary). 
A	reduction	of	ERK1/2	activation	was	also	detected	by	western	blot,	
without	modulation	of	ERK1/2	expression	(Figure	1;	Supplementary).	
We observed no difference in apoptosis levels as shown by annex‐
in‐V cytometric analysis (Supplementary). To evaluate definitely, 
if the phenotypical effects of LEF1‐AS1 overexpression were me‐
diated by LEF1 function, we also overexpressed LEF1‐AS1 in Hela 
(methods in Supplementary), a cell line lacking endogenous expres‐
sion of LEF1 . We observed a reduction in proliferation in LEF1‐AS1 
overexpressing cells using CFSE‐mediated cell division tracking and 
Ki67	staining	(Figure	1E,F),	and	no	effect	upon	LEF1	expression	(no	
detection by RT‐PCR in control and LEF1‐AS1 cells).
Lacking an obvious candidate mediator of this anti‐proliferative 
function of LEF1‐AS1, we resorted to a mass spectrometry‐based 
proteomics approach to characterize the function of LEF1‐AS1. 
Whole‐cell lysates were processed and analysed by Q‐tof mass 
spectrometry. A total of over 500 proteins were identified (see 
complete list in a supplementary file) and 16 were differentially ex‐
pressed (P‐value cut‐off of 0.05, see Table S2). We were able to val‐
idate the most relevant results by western blot (Figure 2A). Histone 
3 (H3), a marker of proliferation,10,11 was reduced, in line with our 
functional results. Talin is a protein involved in cell‐to‐cell and cell‐
to‐substrate adhesion and migration and it has a role in metastasis 
of several cancers, but its contribution to leukaemogenesis is not 
clear. Talin up‐regulation was also observed in Hela and may play 
a role in LEF1‐AS1 function in other tissues (Supplementary). We 
also	validated	 the	 increased	protein	expression	of	RAB7A,	 a	 small	
GTPase that regulates exocytosis/endocytosis‐mediated protein/
RNA trafficking.12	 Remarkably,	 the	 activation	 of	 RAB7A	 is	 associ‐
ated with the increased endocytic degradation of epidermal growth 
factor receptor,13 which suggests a protective role of this protein 
against leukaemogenesis. Among the modulated proteins, fumarase 
or fumarate hydratase (FH) drew our attention as potential mediator 
of the observed reduction in proliferation (Figure 2A). The down‐
regulation of fumarase is accompanied by the consequent intracellu‐
lar accumulation of fumarate (Figure 2B). Remarkably, FH inhibition 
reduces proliferation in THP1, a myeloid cell line,14 and inhibition of 
FH in haematopoietic cells prevents leukaemic transformation, sug‐
gesting it may be a player in the anti‐proliferative effect of LEF1‐AS1 
observed in our experiments.
LEF1‐AS1 and LEF1 expressions in myeloid malignancy were 
quantitatively evaluated by quantitative real‐time polymerase 
chain reaction (qRT‐PCR) using mononuclear cells isolated by Ficoll‐
Hypaque separation from bone marrow samples of 15 controls, 12 
MDS	 patients	 and	 28	 AML	 patients.	We	 observed	 a	 dramatic	 re‐
duction	 of	 LEF1-AS1	 expression	 in	MDS	 and	 AML	 patients	 when	
compared	to	healthy	bone	marrow	donors	(controls	=	15,	MDS	pa‐
tients = 12, fivefold reduction, P = 0.0042, AML patients = 28, sev‐
enfold reduction, P < 0.0001) (Figure 1G). The expression of LEF1 
was	 also	 reduced	 (controls	=	14,	 MDS	 patients	=	12,	 P = 0.0002, 
AML	patients	=	27,	P < 0.0001) (Figure 1G). Although, there is a sig‐
nificant age difference between the groups, no significant correla‐
tion was found between LEF1 or LEF1‐AS1 expression and potential 
F I G U R E  1   A, Relative quantification of LEF1 gene shows no significant modulation of LEF1 at mRNA level in HL60 and efficient 
overexpression of LEF1‐AS1, immunoblot of LEF1 protein in cell lysates of controls and LEF1‐AS1 overexpressing HL60 cells (n = 3, see 
Supplementary	results).	B,	Immunoblots	for	anti-P21,	anti-p27,	anti-ERK1/2	and	anti-phosphoERK1/2	of	control	and	LEF1-AS1	cells	(see	
results from independent experiments in Supplementary), statistical analysis was performed using the relative optical density of the bands 
(Alliance software, Uvitec Ltd.). C, Carboxyfluorescein succinimidyl ester (CFSE) cell division tracking assay of HL60 overexpressing empty 
vector and LEF1‐AS1. Carboxyfluorescein succinimidyl ester fluorescence was measured by flow cytometry. Blue peak: parent cells, orange 
peak:	first	generation	(n	=	3).	D,	HL60	cells	were	labelled	with	allophycocyanin-conjugated	ki67	antibody	and	analysed	by	flow	cytometry,	
LEF1-AS1-HL60	showed	less	positive	Ki67	cells	and	a	reduced	overall	intensity	of	the	proliferation	marker	Ki67	(n	=	3).	E,	Carboxyfluorescein	
succinimidyl ester cell division tracking assay of empty vector and LEF1‐AS1‐Hela. Carboxyfluorescein succinimidyl ester fluorescence 
was measured by flow cytometry. Blue peak: parent cells, orange peak: first generation, green peak: second generation, purple peak: third 
generation.	(n	=	3,	see	Supplementary).	F,	LEF1-AS1-Hela	showed	less	positive	Ki67	cells	and	a	reduced	overall	intensity	of	the	proliferation	
marker	Ki67(SI)	(G)	qRT-PCR	quantification	of	long	non-coding	transcript,	LEF1-AS1	and	LEF1	in	normal	bone	marrow	cells	of	15	controls,	12	
myelodysplastic	syndrome	patients	(MDS)	and	28	acute	myeloid	leukaemia	patients	bone	marrows	(AML).	Lower	relative	expression	levels	
were detected in patients compared with controls. H, Correlation and linear regression between expression of LEF1‐AS1 and survival time 
after diagnosis
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confounders such as age and percentage of blasts in the bone mar‐
row (results section of Supplementary). The suppression of LEF1 in 
myelodysplastic syndrome is well documented8; however, the ex‐
pression pattern of LEF1 in AML had been less clear, and high ex‐
pression of LEF1 has been associated with a favourable prognosis in 
a subtype of AML.15 Here, we show that LEF1 is suppressed in a het‐
erogenous sample of AML and we could not correlate expression of 
LEF1 with patient outcome. Interestingly, despite strong correlation 
between LEF1 and LEF1‐AS1 expression (Supplementary), only LEF1‐
AS1 expression was positively correlated with AML patient survival 
(LEF1‐AS1: P value (two‐tailed) = 0.0423 Pearson r = 0.3934, 95% 
confidence	interval	=	0.01567-0.6729),	Figure	1H.	Supporting	these	
results,	 normal	 haematopoietic	 stem	 cells	 (CD34+HSCs)	 express	
high levels of LEF1‐AS1 when compared to malignant cell lines and 
LEF1‐AS1 expression is particularly suppressed in myeloid malignant 
cells (Figure 2C).
We next examined the anti‐proliferative effects of LEF1‐AS1 in 
mononuclear cells from an AML patient. Transient overexpression of 
LEF1‐AS1 in these cells using Amaxa nucleofector caused a dramatic 
reduction	in	their	colony	formation	capacity	(17-days	methylcellulose	
CFU assay) and a clear reduced cell number after 48 hours of culture 
in expansion medium Stem Span, when compared to empty‐vector 
nucleofected	cells	(Figure	2.D).	Methylcellulose	colony-forming	unit	
(CFU) assay showed that the number of cells capable of forming 
leukaemic cell colonies was reduced as well as colony size in LEF1‐
AS1	nucleofected	cells	after	17	days	 in	semi-solid	culture	 (control:	
54	 colonies,	 LEF1-AS1:	 14	 colonies),	 see	 Figure	 2D	 and	 details	 in	
Supplementary information. RNA was isolated 48 hours after nu‐
cleofection, showing efficient overexpression of LEF1‐AS1 and no 
effect upon LEF1 coding gene (Supplementary).
We observed that LEF1‐AS1 is lost in myeloid malignant cells. 
Expression of LEF1‐AS1 was shown to be reduced in haemato‐
poietic stem cells from myelodysplastic syndrome patients,3 we 
observed	 the	same	pattern	 in	 total	bone	marrow	cells.	MDS	 is	a	
haematologic disorder characterized by blood cytopenia and in‐
creased risk of developing AML.3 This loss of expression is also ob‐
served in AML patients’ bone marrows suggesting this suppression 
may be an important step in malignization and disease progression. 
As we demonstrated, the artificial re‐expression of LEF1‐AS1 re‐
duces proliferation of myeloid cell line HL60, non‐haematopoietic 
F I G U R E  2   A, Validation of proteins 
modulated by LEF1‐AS1 detected by 
mass spectrometry using western 
blot, statistical analysis (paired t test) 
was performed using the relative 
optical densities of the bands of three 
independent experiments (see bands 
used in the analysis in Supplementary). 
B, Measurement of fumarate levels 
between control and LEF1‐AS1‐HL60 
cells. C, Relative expression of LEF1‐AS1 
in	CD34+haematopoietic	stem	cells	(from	
umbilical cord donors, n = 3), several 
myeloid, lymphoid cell lines and Hela 
(n	=	1	of	each).	D,	Microscopic	images	of	
bone marrow mononuclear cells of AML 
patient after 48 h in expansion medium 
(upper panels) and representative colonies 
after	17	d	in	methylcellulose	culture	
(lower panels). Cells nucleofected with 
control (left panels) empty vector and 
LEF1‐AS1(right panels) containing vector
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Hela and AML patient mononuclear cells. Although, the mecha‐
nism by which LEF1‐AS1 regulates cell proliferation remains un‐
clear, our results strongly suggest that LEF1‐AS1 has a protective 
anti‐proliferative role in myeloid malignancy and future work is 
required to understand the molecular functions and implications 
of this transcript in other pathologies.
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